2024
New insights into macrophage polarization and its prognostic role in patients with colorectal cancer liver metastasis
Khanduri I, Maki H, Verma A, Katkhuda R, Anandappa G, Pandurengan R, Zhang S, Mejia A, Tong Z, Solis Soto L, Jadhav A, Wistuba I, Menter D, Kopetz S, Parra E, Vauthey J, Maru D. New insights into macrophage polarization and its prognostic role in patients with colorectal cancer liver metastasis. BJC Reports 2024, 2: 37. PMID: 39516662, PMCID: PMC11523988, DOI: 10.1038/s44276-024-00056-8.Peer-Reviewed Original ResearchColorectal cancer liver metastasesRecurrence-free survivalCancer liver metastasesTumor-associated macrophagesT cell subtypesPreoperative chemotherapyLiver metastasesT cellsColorectal cancer liver metastases patientsM2 macrophagesAssociated with shorter recurrence-free survivalShorter recurrence-free survivalPredictor of favorable prognosisRegulatory T cellsMacrophage polarizationCytotoxic T cellsHelper T cellsDensity of M2 macrophagesCause of mortalityFavorable prognosisPrognostic roleM2 macrophage polarizationTumor biologyTumor samplesColorectal cancer
2022
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
Johnson B, Haymaker C, Parra E, Soto L, Wang X, Thomas J, Dasari A, Morris V, Raghav K, Vilar E, Kee B, Eng C, Parseghian C, Wolff R, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba I, Futreal A, Kopetz S, Overman M. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Journal For ImmunoTherapy Of Cancer 2022, 10: e005332. PMID: 36007963, PMCID: PMC9422817, DOI: 10.1136/jitc-2022-005332.Peer-Reviewed Original ResearchConceptsMicrosatellite stable (MSS) metastatic colorectal cancerTreatment-related adverse eventsMetastatic colorectal cancerResponse rateStable diseasePartial responsePD-1Lung metastasesColorectal cancerT cellsCommon treatment-related adverse eventsMedian age 48 yearsMedian progression-free survivalTumor microenvironmentCombination of trametinibPhase II studyPhase II trialProgression-free survivalCD8 T cellsImmune checkpoint blockadeT cell infiltrationImmune tumor microenvironmentOverall response rateAge 48 yearsComparison of baseline
2021
ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer
Sarshekeh A, Alshenaifi J, Roszik J, Manyam G, Advani S, Katkhuda R, Verma A, Lam M, Willis J, Shen J, Morris J, Davis J, Loree J, Lee H, Ajani J, Maru D, Overman M, Kopetz S. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. Clinical Cancer Research 2021, 27: 1663-1670. PMID: 33414133, PMCID: PMC7956157, DOI: 10.1158/1078-0432.ccr-20-2404.Peer-Reviewed Original ResearchConceptsMicrosatellite stable colorectal cancerColorectal cancerStable colorectal cancerMutant casesCancer Center databaseT-cell markersTumor mutational burdenAT-rich interactive domain 1AUnique molecular subgroupSignificant higher expressionCancer Genome AtlasImmunologic featuresIFNγ expressionImmune activationImmune subtypesTreatment strategiesPreclinical modelsT cellsImmune responseMutational burdenSeparate cohortPatientsTherapy trialsActive subgroupMolecular subgroups